Sort   by:  
 Page size 
ProteomicsTCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors in vivo
CTNNB1/ ꞵ-catenin is mutated in 3.3% of solid cancers, with several recurrent gain-of-function mutations occurring early during cancer formation. This includes the shared driver mutation CTNNB1S37F, estimated to occur in >7000 new cancer cases in 2024 in the US. However, to offer attractive immunoth...
ORGANISM(S): Homo sapiens (Human) 
2025-07-15 | PXD054276 | Pride
Β-catenin In vivo T cells Immunotherapy 
ProteomicsPublic T cell epitopes shared among SARS-CoV-2 Public T cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles variants are presented on prevalent HLA class I alleles
In this project, we used MS-based immunopeptidomics and T-cell screening assays to identify SARS-CoV-2 epitopes. The MS identified epitopes were further valdiated for CD8 T cell immunogenecity. PBMC from a large number of patients infected with SARS-CoV-2 were used for valdiation of MS identifed and...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD028862 | Pride
Sars-cov-2 Lc-ms Immunopeptidomics 
ProteomicsA T-cell receptor targeting a shared neoantigen mediates elimination of primary human acute myeloid leukemia in vivo
This paper presents a T-cell receptor (TCR) reactive to the recurrent D835Y driver mutation in the FLT3 tyrosine-kinase domain. TCRFLT3D/Y-redirected T cells selectively eliminated primary human AML cells harboring the D835Y mutation in vitro and in vivo. The TCRFLT3D/Y cells rejected both CD34+ and...
ORGANISM(S): Homo sapiens (Human) 
2023-08-28 | PXD043908 | Pride
Human Prm Lc-ms Acute myeloid leukemia Cellular immunotherapy 
Sort   by:  
 Page size